Skip to content

Zymeworks ZYME Increase (Decrease) in Deferred Income Taxes

Increase (Decrease) in Deferred Income Taxes at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredIncomeTaxes.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's increase (decrease) in deferred income taxes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's increase (decrease) in deferred income taxes?
Zymeworks (ZYME) reported increase (decrease) in deferred income taxes of $2.2M in Q1 2026.
How has Zymeworks's increase (decrease) in deferred income taxes changed year-over-year?
Zymeworks's increase (decrease) in deferred income taxes increased by 436.6% year-over-year, from $410K to $2.2M.
What is the long-term trend for Zymeworks's increase (decrease) in deferred income taxes?
Over 2 years (2023 to 2025), Zymeworks's increase (decrease) in deferred income taxes has grown at a 11.7% compound annual growth rate (CAGR), from $757K to -$945K.